dc.date.accessioned2019-12-06T21:04:52Z
dc.date.available2019-12-06T21:04:52Z
dc.date.created2019-12-06T21:04:52Z
dc.date.issued2019
dc.identifierhttps://hdl.handle.net/20.500.12866/7654
dc.identifierhttps://doi.org/10.1007/s10815-019-01551-5
dc.description.abstractPurpose: To investigate the effectiveness of a biphasic IVM culture strategy at improving IVM outcomes in oocytes from small follicles (< 6 mm) compared with routine Standard IVM in patients with polycystic ovaries. Methods: This prospective pilot study was performed in 40 women with polycystic ovaries whose oocytes were randomized to two IVM culture methods. Patients received a total stimulation dose of 450 IU rFSH. Cumulus-oocyte complexes (COCs) from follicles < 6 mm and ≥ 6 mm were retrieved and cultured separately in either a prematuration medium with c-type natriuretic peptide followed by IVM (CAPA-IVM), or STD-IVM. Primary outcomes were maturation rate, embryo quality, and the number of vitrified day 3 embryos per patient. Results: Use of the CAPA-IVM system led to a significant improvement in oocyte maturation (p < 0.05), to a doubling in percentage of good and top-quality day 3 embryos per COC, and to an increased number of vitrified day 3 embryos (p < 0.001), compared to STD IVM. Oocytes from follicles < 6 mm benefited most from CAPA-IVM, showing a significant increase in the amount of good and top-quality embryos compared to STD IVM. CAPA-IVM yielded significantly (p < 0.0001) less GV-arrested oocytes and larger oocyte diameters (p < 0.05) than STD IVM. Conclusions: CAPA-IVM brings significant improvements in maturation and embryological outcomes, most notably to oocytes from small antral follicles (< 6 mm), which can be easily retrieved from patients with a minimal ovarian stimulation. The study demonstrates the robustness and transferability of the CAPA-IVM method across laboratories and populations.
dc.languageeng
dc.publisherSpringer
dc.relationJournal of Assisted Reproduction and Genetics
dc.relation1573-7330
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjecthuman
dc.subjectembryo
dc.subjectIVM
dc.subjectpriority journal
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectfemale
dc.subjecthuman cell
dc.subjectadult
dc.subjectclinical outcome
dc.subjectprospective study
dc.subjectclinical article
dc.subjectantral follicle
dc.subjectC-type natriuretic peptide
dc.subjectcell count
dc.subjectcell size
dc.subjectEmbryo
dc.subjectin vitro oocyte maturation
dc.subjectIVF
dc.subjectnatriuretic peptide type C
dc.subjectoocyte development
dc.subjectOocyte prematuration
dc.subjectovary polycystic disease
dc.subjectrecombinant follitropin
dc.subjectvitrification
dc.titleBiphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución